Sotera Health (NASDAQ:SHC) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Sotera Health (NASDAQ:SHC) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $16.08.

A number of equities analysts have issued reports on SHC shares. Citigroup raised their target price on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Barclays cut their price objective on Sotera Health from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Tuesday. The Goldman Sachs Group initiated coverage on Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $17.00 price objective on shares of Sotera Health in a report on Thursday, November 21st.

Sotera Health Price Performance

Shares of SHC opened at $13.52 on Friday. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91. Sotera Health has a 1 year low of $10.71 and a 1 year high of $17.44. The stock has a market cap of $3.83 billion, a P/E ratio of 54.08 and a beta of 1.91. The stock’s 50-day moving average price is $13.45 and its two-hundred day moving average price is $14.56.

Institutional Investors Weigh In On Sotera Health

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in Sotera Health by 19.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock valued at $46,026,000 after acquiring an additional 447,186 shares in the last quarter. Maven Securities LTD bought a new stake in Sotera Health in the 3rd quarter valued at approximately $1,670,000. Cerity Partners LLC bought a new stake in Sotera Health in the 3rd quarter valued at approximately $1,489,000. Neo Ivy Capital Management bought a new stake in Sotera Health in the 3rd quarter valued at approximately $720,000. Finally, Barclays PLC increased its position in shares of Sotera Health by 169.8% during the 3rd quarter. Barclays PLC now owns 473,597 shares of the company’s stock worth $7,909,000 after purchasing an additional 298,085 shares during the last quarter. Institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.